TrialArthritis care & research2017

Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

D van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.